Biomimetic Elastin-Like Polypeptides as Materials for the Activation of Mechanophoric Catalysts

Sebastian Funtan^a Anne Funtan^b Reinhard Paschke^bWolfgang H. Binder^{*a}

^aMacromolecular Chemistry, Institute of Chemistry, Faculty of Natural Science II, Martin Luther University Halle-Wittenberg, Von-Danckelmann-Platz 4, 06120 Halle (Saale), Germany

^bBiozentrum, Martin Luther University Halle-Wittenberg, Weinbergweg 22, 06120 Halle (Saale), Germany
wolfgang.binder@chemie.uni-halle.de

Received: 26.11.2019

Accepted after revision: 31.12.2019

DOI: 10.1055/s-0040-1702149; Art ID: 190023

License terms:

© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abstract Elastin-like polypeptides (ELPs) are well known for their elastic and thermoresponsive behaviors. Their elasticity originates from the formation of a β -spiral which is the consequence of stacking type-II β -turns, formed from individual VPGVG pentapeptide units. Here, the synthesis of ELPs of varying chain lengths [VPGVG, (VPGVG)₂, and (VPGVG)₄] and their coupling to a mechanoresponsive catalyst are reported. The attached ELP chains can act as “molecular springs,” allowing for an efficient uptake and transmission of an applied force to the mechanophoric bond. This leads to stress-induced activation of the mechanophoric catalyst, in turn transforming mechanical energy into a “click” reaction. Secondary structure analysis via IR and CD spectroscopy revealed that the β -spiral formation of the ELP is not affected by the coupling process and the β -spiral is still intact in the mechanocatalyst after the coupling. Mechanochemical activation of the synthesized catalysts by an external applied force, studied via ultrasonication, showed conversions of the copper(I)-catalyzed alkyne-azide “click” reaction (CuAAC) up to 5.6% with an increasing chain length of the peptide, proving the potential to incorporate this chemistry into biomaterial engineering.

Key words Elastin-like polypeptides, β -spiral, peptide coupling, copper(I), “click” reaction, mechanochemistry, mechanocatalysts

Introduction

Elastin-like polypeptides (ELPs) are artificial derivatives of elastin, a highly cross-linked, extracellular matrix protein, that is responsible for elasticity and resilience of tissues that repeatedly undergo extension and retraction such as ligaments and arteries.^{1–5} ELPs consist of short amino

acid sequences, being part of the elastin sequence, whose polymerization leads to polypeptides with similar thermoresponsive and elastic (when cross-linked) behaviors compared to native elastin.^{6,7} The pentapeptide VPGVG is of special interest because it is the most prominent amino acid sequence of native elastin.^{8,9} While native elastin is insoluble due to cross-linking, ELPs as a soluble alternative to elastin allowed detailed investigation of the origin of elasticity and this led to the development of the fibrillar model.^{10–15} Using the VPGVG sequence it was found that each pentapeptide unit forms a type-II β -turn independently from the other units.^{10,16–18} Several β -turns will stack on each other, leading to the formation of a loose helix, also called β -spiral. The β -spiral is kinetically free to undergo librational or rocking motions, but stretching dampens these motions and the number of states of equivalent energy is drastically reduced, in turn providing the restoring force for elasticity.¹²

Since an efficient force transmission plays a crucial role in the field of mechanochemistry, ELPs are perfectly tailored to take up and redirect an applied force to the mechanophoric bond, thus acting as “molecular springs.”^{12,19,20} Mechanophores contain one or more mechanically labile bonds, functional groups that are inactive in their initial state but can respond to an external applied force. Once activated, mechanophores can undergo a variety of mechanochemical transformations such as color changes,^{21–23} chemiluminescence,^{24,25} activation of latent metal catalysts,^{26–34} biased reactivity,³⁵ release of small molecules,^{36,37} generation of protons,³⁸ and also remodeling of polymers.³⁹ Besides the correct positioning of the mechanophoric bond near the center of the molecule, the attached polymer chains play a crucial role since they take up and transmit the force along the polymer backbone.^{40,41} We previously have designed latent Cu(I) bis(*N*-heterocyclic carbene) (NHC) catalysts as mechanophores for the time- and spatial-controlled copper(I)-catalyzed alkyne-azide “click” reaction (CuAAC).^{28,29,31,33} The ability of the attached polymer chains to transmit an applied force was controlled via the *T_g* of the chosen polymer

Figure 1 The bifunctional mechanocatalysts bearing either two carboxyl or two amino groups are used for coupling reactions via the *N*- or the *C*-terminus of peptides.

[poly(isobutylene), poly(styrene), and poly(tetrahydrofuran)]. Exchanging the synthetic polymer handles with peptides thus is a promising way to study force transmission, since the resulting β -spiral structures could be exploited as “molecular springs.”

As published previously, in the first step, two low-molecular weight Cu(I) bis(NHC) mechanophoric catalysts bearing either two carboxyl groups $\{[\text{Cu}(\text{C}_{10}\text{COOH-NHC})_2]\text{Br}\}$ (**1**) or two amino groups $[\text{Cu}(\text{C}_3\text{NH}_2\text{-NHC})_2\text{Br}]$ (**2**) (see Figure 1) were designed, enabling peptide coupling reactions with the *N*- or the *C*-terminus of peptides.⁴² The first few reactions revealed a persisting mechanophoric behavior after coupling of single amino acids (Gly and Val).

In the present article, we stepwise extended the amino acid sequence [VG, VPG, VPGVG, (VPGVG)₂, and (VPGVG)₄] and coupled it to the latent mechanophoric Cu(I) bis(NHC) complexes **1** and **2**, yielding mechanophores with varying peptide chain lengths. In addition to the linear catalysts, resulting from the coupling of **1** with the *N*-terminus-deprotected peptides, we also generated chain-extended structures. Therefore, **1** and **2** were polymerized with the *C*- and *N*-terminus-deprotected VPGVG sequence. Secondary structure analysis via IR and CD spectroscopy were conducted to probe whether the conformation of the

peptide is affected by the coupling to the mechanophoric catalyst. Subsequently, ultrasonication was used to investigate the mechanochemical activation of all synthesized peptide-bearing catalysts by an external applied force.

Results and Discussion

The (VPGVG)₄ sequence was built up via solution-phase peptide synthesis, starting from the single amino acids shown in Scheme 1, following common coupling protocols.⁴³ The *tert*-butoxycarbonyl (Boc) protecting group was used for the *N*-terminus, while the *C*-terminus was methyl ester (OMe) protected to ensure that it follows an orthogonal protecting-group strategy. In the first step, glycine methyl ester hydrochloride (**3**), *N*-(*tert*-butoxycarbonyl)-*L*-proline (**4**), and *N*-(*tert*-butoxycarbonyl)-*L*-valine (**5**) were synthesized. Coupling of **3** and **5** using the common peptide coupling agents 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCl) and 1-hydroxybenzotriazole (HOBt) yielded the dipeptide **6**, which was then deprotected with trifluoroacetic acid (TFA) to generate the *N*-terminus-deprotected dipeptide **7**. Coupling of **3** and **4** generated the dipeptide **8**, which was also *N*-terminus-deprotected, in turn generating **9**. Subsequent coupling with **5** led to the formation of the tripeptide **10**, which was dissolved in H₂O and THF (4:3) and stirred in the presence of lithium hydroxide to obtain the *C*-terminus-deprotected tripeptide **11**. **10** was also deprotected at the *N*-terminus to yield peptide **12**, which later was coupled to the mechanophoric catalyst **1**. Coupling of **7** and **11** generated the pentapeptide **13**, which is known to be one of the most important ELP sequences.⁴ The ¹H NMR spectrum of **13** is shown in Figure 2c (for ¹H and ¹³C NMR spectra of the other peptides, see the Supporting Information), proving that both protection groups are still present after the

Scheme 1 Synthetic approach for the elastin-like polypeptide sequence starting from single amino acids. *C*- and *N*-terminus protection steps for the single amino acids are not shown.

Figure 2 Chemical structures of (a) pentapeptide **13** and (b) the mechanophoric catalyst **22c** bearing the pentapeptide. ^1H NMR spectra of (c) pentapeptide **13** and (d) the mechanophoric catalyst **22c** bearing the pentapeptide.

coupling. The Boc group gave a resonance at 1.35 ppm, while the methyl ester group could be assigned to the signal at 3.60 ppm, overlapping with proton H-8. Splitting product **13** to deprotect the *N*-terminus of one half and the C-terminus of the other half generated peptides **14** and **15**, which afterwards could be coupled to obtain the decapeptide **17**. A small portion of peptide **15** was also deprotected at the *N*-terminus,

generating the double-deprotected peptide **16**, which subsequently was used for the synthesis of the chain-extended catalyst. Once more splitting of peptide **17** followed by *N*- and C-terminus protection yielded peptides **18** and **19**, which were subsequently coupled to the eicosapeptide **20**. Stirring **20** in the presence of TFA generated **21** with an unprotected *N*-terminus.

In the next step, peptide coupling reactions were performed to couple the peptides **7**, **12**, **14**, **18**, and **21** to **1**, yielding the mechanophoric catalysts **22a–e** as shown in Scheme 2. **22f** was generated by polycondensation of **16** with **1** and **2**, leading to polymeric structures with molecular weights of up to 4500 g mol^{-1} [see the Supporting Information for gel permeation chromatography (GPC) trace]. For the coupling reactions, *N,N'*-dicyclohexylcarbodiimide (DCC) and pentafluorophenol were chosen as reagents due to the higher yields in comparison to EDC-HCl and HOBt, as reported previously.⁴² While the shorter peptides **7** and **12** were still soluble in dichloromethane (DCM), dimethylformamide (DMF) was chosen as a solvent for the longer peptides **14**, **16**, **18**, and **21**. Figure 2d shows the ^1H NMR of **22c** after the workup, which proved that the catalyst was not destroyed during the coupling process (for ^1H and ^{13}C NMR of the other catalyst-peptide conjugates, check the Supporting Information). Destruction of the catalyst would lead to a resonance at $\sim 10.50\text{ ppm}$ due to destruction of the copper-carbene bond, leading to reprotonation of C-2 (for the full ^1H NMR spectrum, see the Supporting Information). Furthermore, matching integrals for both signals $\{[\text{Cu}(\text{C}_{10}\text{COOH-NHC})_2]\text{Br}$ and pentapeptide} proved a quantitative coupling reaction.

Since the peptides were coupled to the mechanophore with the aim to exploit their “molecular spring” behavior, it was essential to check if the coupling affected the ability of the peptide to form the β -spiral. We therefore performed IR and CD investigations to obtain information about the secondary structure of pentapeptide **13** and compared the obtained

Scheme 2 Synthetic approach for the coupling of the ELP sequences to the mechanophoric catalysts. (a) Coupling of the *N*-terminus-deprotected peptides with varying chain lengths to **1**. (b) Polycondensation of **1**, **2**, and the *N*- and C-terminus-deprotected pentapeptide **16** generates the chain-extended catalyst **22f**.

results with those of the mechanophoric catalyst **22c**, which also bears the pentapeptide sequence. IR analysis of the amide I band (1600–1690 cm⁻¹) is frequently used to gain information about the secondary structure of peptides.⁴⁴ The measurements were performed in D₂O since it does not show any absorption in this region, in contrast to H₂O (H–O–H bending at 1645 cm⁻¹). Within the amide I band, the IR of **13** showed two maxima at 1654 and 1618 cm⁻¹ as shown in Figure 3a. It was previously reported by Franzen et al. that this double-peaked amide I band is the signature for the β -spiral and should not mistakenly be assigned to a α -helical structure (usually occurring at 1653 $\pm$ 3 cm⁻¹).^{44,45} Formation of the β -spiral was observed at three concentrations (10, 7.5, and 5 mg mL⁻¹). Normalization of the IR spectra to the maximum at 1740 cm⁻¹ (originating from the methyl ester protection group) revealed that the formation of the β -spiral was not influenced within the tested concentration range (see the Supporting Information). Coupling of the pentapeptide to

the mechanophoric catalyst did not influence the β -spiral formation as shown in the amide I band from **22c** in Figure 3b. The double-peaked spectrum with two maxima at 1618 and 1654 cm⁻¹ was still visible for the mechanophoric catalyst. IR spectra were recorded at the same concentrations (10, 7.5, and 5 mg mL⁻¹) as done for **13**. Normalization to the maximum at 1740 cm⁻¹ again showed that β -spiral formation was not influenced in the tested concentration range (see the Supporting Information). Overlaying the two measurements of **13** and **22c** at 10 mg mL⁻¹ clearly showed that there was no shift in the absorbance maxima after the coupling reaction, as shown in Figure 3c. It is noteworthy that the β -spiral formation was not disturbed if two pentapeptide units were linked together via the mechanophore (**22c**). As demonstrated earlier by Guan and Chen, each pentapeptide unit forms the β -spiral structure independently from other pentapeptide units.⁴³ To ensure that the “molecular spring” behavior of the peptide is the result of a β -spiral and not of an α -helix, we also measured CD spectroscopy of **13** and **22c**, to obtain further information about the secondary structure of the peptides.⁴⁶ CD measurements were performed in D₂O at concentrations of 0.4 mg mL⁻¹ and the results are shown in Figure 4. The measurement results for **13**, showing one maximum at 208 nm and one minimum at 226 nm, clearly indicated the presence of a β -sheet as the only secondary-structure element, while there was no evidence for the presence of α -helical secondary structures. Similar to the IR spectroscopy results, the CD spectrum of **22c** was identical to that of **13**, still showing only β -sheet conformation and no α -helical structures. Accordingly, an adoption of a β -spiral structure could be concluded for the pentapeptide sequence. Coupling to the [Cu(C₁₀COOH–NHC)₂]Br mechanophore did not prevent the secondary structure formation, thus allowing the coupled peptide sequence to act as a “molecular spring.”

We subsequently tested the mechanoresponsive behavior of the synthesized mechanophoric catalysts **22a–f** using a model CuAAC “click” reaction between benzyl azide (**23**)

and phenylacetylene (**24**). The switching of latent Cu(I) bis(NHC) complexes to their active state after exposure to mechanical stress, for example in the form of ultrasound (in solution) or compression (in bulk), has been previously described.^{28,29,31,33,42} While in its latent state, the Cu(I) center is shielded by the two NHC ligands, preventing the alkyne from coordination to the Cu(I). Once an external force is applied, one of the NHC ligands is cleaved off from the Cu(I) center due to the rupture of the copper–carbene bond. The exposed Cu(I) center is no longer shielded from the alkyne, in turn allowing the formation of the copper acetylide, which is known to be a crucial step in the “click” reaction (Figure 5).⁴⁷ Activation of the catalyst to its monocarbene form was observed by following the “click” reaction of **23** and **24** via ¹H NMR spectroscopy. Therefore, samples were taken after the 3rd, 5th, 10th, 14th, and 17th cycles of ultrasonication. Calculation of the “click” conversion in dependence of the sonication time was done by observing the shifts from the methylene group of **23** from 4.35 to 5.59 ppm for the “click” product **25** as well as an increasing triazole resonance at 8.11 ppm. Activation of the latent catalyst could also be followed by observing the decreasing resonances of the NHC protons (H-3 and H-4) with proceeding ultrasonication cycles. Calculation for catalyst **22c** is shown exemplary in the Supporting Information and activation was found to be ~30% after the last cycle.

Ultrasonication experiments revealed that a stepwise extension of the attached peptide chain to the mechanophoric catalyst led to an increase of its catalytic activity (for a tabular overview including control experiments without ultrasonication, check the Supporting Information). Thus, the “click” conversion could be increased from 3.4% for catalyst **1** [$\text{Cu}(\text{C}_{10}\text{COOH-NHC})_2\text{Br}$], which does not bear a peptide chain, to 5.6% for the catalyst with the longest peptide chain **22e** [$\text{Cu}(\text{C}_{10}\text{COOH-(VPGVG)}_4\text{-NHC})_2\text{Br}$]. The chain-extended catalyst **22f**, bearing the pentapeptide moiety between the mechanophoric units, showed a slightly lower activity in comparison to **22e** with a conversion of 4.7%.

In order to test the biocompatibility of the synthesized catalysts, we also performed cytotoxicity tests for two

different cell lines (MCF7 and NIH/3T3) of the complexes **1** and **2** (being devoid of the ELP sequence), **22c** (bearing the ELP sequence), and fluorotris(triphenylphosphine)copper(I) (bearing no shielding NHC ligands; see the Supporting Information), as the cytotoxicity of some Cu(I) species is described in the literature.^{48,49} Cell toxicity tests with fluorotris(triphenylphosphine)copper(I) revealed high toxicity with ~50% of the cells being alive at concentrations of $\sim 4 \mu\text{mol L}^{-1}$ for both cell lines (MCF7 and NIH/3T3). Already complexes **1** and **2** showed a reduced toxicity with ~50% of the cells being still alive at catalyst concentrations of $75 \mu\text{mol L}^{-1}$. Coupling of the peptide to the catalyst further decreased the cytotoxicity. Half of the cells were still alive at a concentration of $\sim 150 \mu\text{mol L}^{-1}$, proving an increased biocompatibility due to the shielding effect of the attached ELP chains from the Cu(I) for the cells. However, all results were similar for both cell lines (MCF7 and NIH/3T3), showing low selectivity for tumor cells.

Conclusion

In summary, we successfully synthesized and coupled ELP sequences of different chain lengths [VG, VPG, VPGVG, (VPGVG)₂, and (VPGVG)₄] to the mechanophoric catalyst $[\text{Cu}(\text{C}_{10}\text{COOH-NHC})_2]\text{Br}$. Furthermore, a chain-extended catalyst was synthesized using the N- and C-terminus-deprotected pentapeptide TFA-H₂N-VPGVG-OH and the two catalysts $[\text{Cu}(\text{C}_{10}\text{COOH-NHC})_2]\text{Br}$ and $[\text{Cu}(\text{C}_3\text{NH}_2\text{-NHC})_2]\text{Br}$. Secondary structure analysis via IR and CD spectroscopy revealed that the β -spiral forming behavior of the pentapeptide VPGVG sequence was still present after the coupling to the Cu(I) bis(NHC) complex, allowing the exploitation of the “molecular spring” behavior. The mechanoresponsive behavior was tested with ultrasonication experiments in solution using a model “click” reaction and was still present after the coupling reactions, showing an increased cleavage efficiency with an increasing chain length from 3.4% (**1**) to 5.6% (**22e**).

Experimental Section

All chemicals were obtained from commercial suppliers and were used without further purification. The mechanophoric catalysts $[\text{Cu}(\text{C}_{10}\text{COOH-NHC})_2]\text{Br}$ (**1**) and $[\text{Cu}(\text{C}_3\text{NH}_2\text{-NHC})_2]\text{Br}$ (**2**) were synthesized as reported previously.⁴² DCM and DMF were dried with calcium hydride, freshly distilled, and degassed by bubbling nitrogen for at least 20 min prior to use.

¹H NMR and ¹³C NMR spectra were recorded either on a Varian Gemini 200 (400 MHz; Agilent, Germany) or on a Varian Unity Inova (500 MHz, Agilent, Germany) spectrometer. All chemical shifts (δ) are given in part per million (ppm)

Figure 5 The latent catalyst was activated via ultrasonication leading to a cleavage of one of the two shielding NHC ligands which allowed the alkyne to coordinate to the Cu(I) center triggering thus the “click” reaction.

and were referred to the solvent residual signal [CDCl_3 : 7.26 ppm (^1H NMR), 77.0 ppm (^{13}C NMR); $\text{DMSO}-d_6$: 2.50 ppm (^1H NMR), 39.5 ppm (^{13}C NMR)] and J values are given in hertz (Hz).

GPC measurements were performed on a Viscotek GPCmax VE 2001 (Malvern Panalytical Ltd., UK) using a $\text{H}_{\text{HR}}\text{-H}$ Guard-17369 (Malvern Panalytical Ltd., UK) and a $\text{GM}_{\text{HR}}\text{-N}$ -18055 column (Malvern Panalytical Ltd., UK) with DMF containing 10 mM LiTf_2N as an eluent at 60 °C and via detection of the refractive index with a Viscotek VE 3580 RI detector (Malvern Panalytical Ltd., UK) at 35 °C. The external calibration was done using polystyrene standards ($\text{MP} = 1000\text{--}115,000 \text{ g mol}^{-1}$). The concentration of all samples was 5 mg mL^{-1} and the flow rate was 1 mL min^{-1} .

ESI-TOF MS measurements were performed on a Bruker Daltonics microTOF (Bruker Daltonics, Germany) via direct injection with a flow rate of $180 \mu\text{L h}^{-1}$ using either the positive or the negative mode. Samples were prepared by dissolving the sample in a HPLC-grade solvent at a concentration of 1 mg mL^{-1} without salt addition.

Fourier-transform infrared spectroscopy was performed on a VERTEX 70 IR spectrometer (Bruker, Germany) by using a single reflex-diamond attenuated total reflectance unit for solid-state investigations. Solution experiments were performed in D_2O using a Specac Omni Cell demountable cell with CaF_2 windows (Sigma Aldrich, Germany) and a polytetrafluoroethylene (PTFE) spacer of 0.1 mm. The pure solvent was measured as a background and the absorption bands are reported in cm^{-1} .

CD spectroscopy measurements were performed on a Jasco J-810 instrument (Jasco, Germany) at 20 °C using a cuvette with a space length of 0.1 mm and a sample concentration of 0.4 mg mL^{-1} in D_2O . Spectra were measured with a wavelength range of 250 to 195 nm and a scan rate of 1 nm s^{-1} performing 50 accumulations.

Ultrasonication experiments were conducted by placing the latent mechanocatalyst ($7.50 \mu\text{mol}$) into a 10-mL reaction vessel with two additional side necks attached to a VCX 500 ultrasonic processor (Sonics & Materials, CT, USA) equipped with a long full-wave solid probe and an internally threaded stainless steel adapter. The vessel was evacuated and flushed with nitrogen at least three times to remove oxygen. Subsequently, benzyl azide ($750.0 \mu\text{mol}$) and phenylacetylene ($750.0 \mu\text{mol}$) were added as well as 10.0 mL of a THF- d_8 /MeOH [30:1 (v/v)] mixture which resulted in a catalyst concentration of 0.75 mM. To the mixture, successive cycles of pulsed ultrasound with a frequency of 20 kHz using 20% of the maximal amplitude (experiments with 30% maximal amplitude were not successful) with a sequence of 5 s pulse and 10 s break for 90 min were applied corresponding to an ultrasound power intensity of 4.66 W cm^{-1} and an energy input of 11 kJ. During this time, the mixture was cooled in a water bath to prevent the temperature from rising above 25 °C. Each cycle was followed by a waiting time of 60 min. Samples were taken

after the cycles 0, 3, 5, 10, 14, and 17 and the conversion of the “click” reaction was checked via ^1H NMR spectroscopy by observing the increase in the triazole resonance at 8.11 ppm as well as the shift of the methylene group from 4.35 to 5.59 ppm. Control experiments without ultrasound were carried out in two-necked flasks at room temperature as well as at 60 °C to prove the activation of the catalyst by ultrasound (for control experiments, see the Supporting Information).

Cytotoxicity tests were evaluated by the sulforhodamine B (SRB; Sigma Aldrich, Germany) micro culture colorimetric assay. Exponentially growing cells were seeded into 96-well plates on day 0 at the appropriate cell densities to prevent confluence of the cells during the period of the experiment. After 24 h, the cells were treated with serial dilutions of the compounds (0–150 μM) for 72 h. After 72 h treatment, the supernatant medium was discarded from the 96-well plates and the cells were fixed with 10% trichloroacetic acid. For a thorough fixation, the cells were allowed to stand at 4 °C for at least 2 h. After fixation the cells were washed in a plate washer (Tecan Austria GmbH, Austria). The washing step was done five times with water using alternate dispensing and aspiration procedures. The plates were then stained with 100 μL of 0.4% SRB in a 1% acetic acid solution for about 45 min. After staining, the plates were washed with 1% acetic acid to remove the dye and allowed to air-dry overnight. 100 μL of 10 mM tris base solution was added to each well and the absorbance was measured at a wavelength of 570 nm using a plate reader (Tecan Infinite F200 Pro, Austria).

Thin-layer chromatography (TLC) was performed using Merck silica gel 60 plates (Merck, Germany). Spots on the TLC were visualized using an oxidizing agent blue stain or potassium permanganate solution or UV light (256 or 366 nm). The blue staining solution was prepared as follows: $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24}\cdot 4\text{H}_2\text{O}$ (1.0 g) and $\text{Ce}(\text{SO}_4)_2\cdot 4\text{H}_2\text{O}$ (1.0 g) were dissolved in a mixture of distilled water (90.0 mL) and concentrated sulfuric acid (6.0 mL). The potassium permanganate solution was prepared as follows: KMnO_4 (3.0 g) and K_2CO_3 (20.0 g) were dissolved in H_2O (300 mL) and 10% NaOH (5.0 mL). Column chromatography was carried out using silica gel high-purity grade, 60 Å pore size, 230–400 mesh particle size (Merck, Germany).

^1H and ^{13}C NMR spectra: for numbering of carbon atoms, see the Supporting Information.

Procedures

Synthesis of Glycine Methyl Ester Hydrochloride (3)

Glycine (5.0 g; 66.6 mmol, 1.0 equiv.) was dissolved in MeOH (65.0 mL) and cooled down to 0 °C using an ice bath. SOCl_2 (8.70 g; 73.3 mmol, 1.1 equiv.) was slowly added under stirring of the solution. Subsequently the reaction mixture was heated to 55 °C for 4 h and then cooled down to room temperature. After stirring overnight, the solvent and the excess of SOCl_2 were removed under vacuum.

Recrystallization from MeOH yielded the pure product as white crystalline needles.⁵⁰

White solid; yield: 6.58 g (79%).

IR (cm⁻¹): 2880 (s), 2686 (w), 2634 (w), 1742 (s), 1583 (m), 1556 (w), 1494 (m), 1458 (w), 1437 (w), 1423 (w), 1400 (w), 1245 (s), 1140 (w), 1096 (w), 1058 (s), 955 (m), 899 (s), 878 (s), 677 (w), 588 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 8.54 (s, 3 H, NH), 3.77 (s, 2 H, H-3), 3.73 (s, 3 H, H-1).

¹³C NMR (100 MHz, DMSO-d₆): δ = 167.9 (C-2), 52.4 (C-1), 39.4 (C-3).

MS (ESI, 70 eV): *m/z* [M + H]⁺ calcd for [C₃H₈NO₂]⁺: 90.1429; found: 90.0550.

General Procedure for the *N*-(*tert*-Butoxycarbonyl) Protection

The corresponding amino acid (42.9 mmol; 1.0 equiv.) and NaOH (42.9 mmol, 1.0 equiv.) were dissolved in water (80.0 mL). Di-*tert*-butyl dicarbonate (47.2 mmol; 1.1 equiv.) was dissolved in 1,4-dioxane (80.0 mL) and was slowly added to the reaction mixture which was cooled via an ice bath. The mixture was left to stir for 48 h at room temperature and was concentrated to ~50.0 mL afterwards. EtOAc (150.0 mL) was added and the pH was adjusted to 2 with aqueous KHSO₄ (10 wt%). The aqueous phase was extracted with EtOAc (1 × 150.0 mL, 6 × 50.0 mL) and the combined organic phases were washed with water (20.0 mL) afterwards. After drying over Na₂SO₄ and filtration, the solvent was removed and the product was obtained as a highly viscous and sticky oil which slowly started to crystallize in the fridge.⁵¹

N-(*tert*-Butoxycarbonyl)-*L*-proline (**4**)

White solid; yield: 8.45 g (88%).

IR (cm⁻¹): 2968 (w), 2895 (w), 1735 (s), 1632 (s), 1478 (w), 1425 (s), 1367 (w), 1332 (w), 1253 (w), 1208 (m), 1187 (w), 1161 (m), 1129 (m), 1089 (w), 978 (w), 898 (w), 852 (w), 791 (w), 774 (w), 761 (w), 640 (w), 587 (w).

¹H NMR (400 MHz, CDCl₃): δ = 9.57 (s, 1 H, COOH), 4.33 (m, 1 H, H-7), 3.45 (m, 2 H, H-4), 2.27 (m, 2 H, H-6), 1.93 (m, 2 H, H-5), 1.47 (d, 9 H, H-1).

¹³C NMR (100 MHz, CDCl₃): δ = 178.8/175.0 (C-8), 156.4 (C-3), 154.1 (C-3), 81.5 (C-2), 80.3 (C-2), 59.2 (C-7), 58.9 (C-7), 47.0 (C-4), 46.3 (C-4), 30.8 (C-6), 28.5 (C-6), 28.4 (C-1), 24.3 (C-5), 23.6 (C-5).

MS (ESI, 70 eV): *m/z* [M - H]⁻ calcd for [C₁₀H₁₆NO₄]⁻: 214.1074; found: 214.1161.

N-(*tert*-Butoxycarbonyl)-*L*-valine (**5**)

White solid; yield: 8.12 g (88%).

IR (cm⁻¹): 3302 (w), 2973 (w), 2937 (w), 2512 (w), 1702 (s), 1644 (s), 1476 (w), 1456 (w), 1405 (s), 1369 (m), 1346 (w), 1310 (w), 1274 (m), 1254 (w), 1188 (w), 1158 (s), 1125

(w), 1094 (w), 1010 (w), 982 (w), 959 (w), 897 (w), 857 (w), 842 (w), 781 (w), 744 (w), 685 (w), 658 (w), 595 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 12.43 (s, 1 H, COOH), 6.88 (d, ³*J* = 8.5 Hz, 1 H, NH), 3.76 (dd, *J* = 8.5, 6.1 Hz, 1 H, H-3), 1.97 (td, *J* = 13.4, 6.8 Hz, 1 H, H-2), 1.36 (s, 9 H, H-7), 0.85 (t, ³*J* = 6.5 Hz, 6 H, H-1).

¹³C NMR (100 MHz, DMSO-d₆): δ = 173.4 (C-4), 155.8 (C-5), 77.9 (C-6), 59.0 (C-3), 29.4 (C-2), 28.1 (C-7), 19.1 (C-1), 18.1 (C-1).

General Procedure for the Peptide Coupling

The Boc-protected peptide (7.96 mmol; 1.0 equiv.), EDC·HCl (9.56 mmol; 1.2 equiv.), and HOBt (9.56 mmol; 1.2 equiv.) were dissolved in dry DMF (80.0 mL). The mixture was cooled down to 0 °C in an ice bath and was stirred for 30 min after the addition of DIPEA (28.67 mmol; 3.6 equiv.). Subsequently, the methyl-ester-protected peptide (7.96 mmol; 1.0 equiv.) was dissolved in DMF (40.0 mL) and was slowly added to the solution. The reaction was stirred for further 48 h before the solvent was removed under reduced pressure. The residue was dissolved in EtOAc (150.0 mL) and water (100.0 mL). Afterwards the organic layer was washed with HCl (1M, 20.0 mL), saturated NaHCO₃ solution (20.0 mL), and brine (50.0 mL). The organic layer was dried over Na₂SO₄ before it was filtrated and the solvent was removed. The crude product was either recrystallized (EtOAc-petrol ether) or purified via column chromatography (DCM-MeOH, 80:1 @ 5:1).⁴³

General Procedure for the Boc Deprotection

The Boc-protected peptide (4.58 mmol; 1.0 equiv.) was dissolved in DCM (10.0 mL). The mixture was cooled down to 0 °C with an ice bath before TFA (51.75 mmol; 11.3 equiv.) was added. The mixture was stirred for 17 h at room temperature. Afterwards the solvent and the TFA were removed under vacuum.

General Procedure for the Methyl Ester Deprotection

The peptide (5.50 mmol; 1.0 equiv.) was dissolved in THF (55.0 mL) and the mixture was cooled down to 0 °C. LiOH·H₂O (22.16 mmol; 4 equiv.) was dissolved in water (72.0 mL) and added to the reaction mixture. After 14 h of stirring at room temperature, the pH was adjusted to 4 by adding 1M HCl. After extraction with EtOAc (6 × 50.0 mL), the combined organic phases were dried over Na₂SO₄, filtered, and the solvent was removed.

Boc-VG-OMe (**6**)

White solid; yield: 16.6 g (72%).

IR (cm⁻¹): 3314 (w), 2959 (w), 1749 (m), 1687 (w), 1655 (s), 1551 (w), 1524 (s), 1438 (w), 1416 (w), 1386 (w), 1367 (w), 1298 (w), 1246 (w), 1210 (m), 1168 (w), 1087

(w), 1045 (w), 1020 (w), 985 (w), 914 (w), 705 (w), 660 (w), 573 (w).

^1H NMR (400 MHz, CDCl_3): δ = 6.59 (s, 1 H, NH), 5.08 (d, 3J = 7.7 Hz, 1 H, NH), 4.04 (m, 3 H, H-4 + H-8), 3.74 (s, 3 H, H-10), 2.18 (td, J = 13.4, 6.8 Hz, 1 H, H-5), 1.43 (s, 9 H, H-1), 0.97 (dd, J = 20.0, 6.8 Hz, 6 H, H-6).

^{13}C NMR (100 MHz, CDCl_3): δ = 171.8 (C-7), 170.0 (C-9), 155.8 (C-3), 79.9 (C-2), 59.8 (C-4), 52.3 (C-10), 41.0 (C-8), 30.7 (C-5), 28.2 (C-1), 19.1 (C-6), 17.5 (C-6).

MS (ESI, 70 eV): m/z $[\text{M} + \text{Na}]^+$ calcd for $[\text{C}_{13}\text{H}_{24}\text{N}_2\text{O}_5\text{Na}]^+$: 311.2485; found: 311.1577.

TFA- H_2N -VG-OMe (7)

Yellow, sticky liquid; yield: 9.32 g (98%).

IR (cm^{-1}): 2970 (w), 1744 (m), 1665 (s), 1530 (w), 1438 (w), 1369 (w), 1178 (s), 1132 (s), 1034 (w), 981 (w), 837 (m), 799 (m), 721 (s), 596 (w).

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.87 (t, 3J = 5.7 Hz, 1 H, NH), 8.13 (s, 3 H, NH_3^+), 3.89 (m, 2 H, H-5), 3.63 (m, 4 H, H-3 + H-7), 2.07 (m, 1 H, H-2), 0.93 (dd, 3J = 6.9, 3.5 Hz, 6 H, H-1).

^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 170.2 (C-4), 168.9 (C-6), 57.6 (C-3), 52.2 (C-7), 41.0 (C-5), 30.2 (C-2), 18.5 (C-1), 18.0 (C-1).

MS (ESI, 70 eV): m/z $[\text{M}]^+$ calcd for $[\text{C}_8\text{H}_{17}\text{N}_2\text{O}_3]^+$: 189.1234; found: 189.1242.

Boc-PG-OMe (8)

White solid; yield: 11.72 g (52%).

IR (cm^{-1}): 3300 (w), 2973 (w), 1753 (m), 1704 (w), 1685 (m), 1660 (m), 1529 (w), 1479 (w), 1409 (s), 1364 (m), 1258 (w), 1213 (w), 1159 (s), 1124 (w), 1089 (w), 1039 (w), 1020 (w), 978 (w), 921 (w), 854 (w), 782 (w), 755 (w).

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.22 (s, 1 H, NH), 4.08 (m, 1 H, H-7), 3.81 (qd, J = 17.3, 5.9 Hz, 2 H, H-9), 3.60 (s, 3 H, H-11), 3.36 (m, 1 H, H-4), 3.26 (m, 1 H, H-4), 2.09 + 1.79 (m, 4 H, H-5 + H-6), 1.32 (d, 9 H, H-1).

^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 173.5 (C-8), 170.6 (C-10), 153.6 (C-3), 78.9 (C-2), 60.0 (C-7), 52.1 (C-11), 46.8 (C-4), 40.9 (C-9), 31.4 (C-6), 28.6 (C-1), 28.4 (C-1), 23.5 (C-5).

MS (ESI, 70 eV): m/z $[\text{M} + \text{Na}]^+$ calcd for $[\text{C}_{13}\text{H}_{22}\text{N}_2\text{O}_5\text{Na}]^+$: 309.1418; found: 309.1421.

TFA- H_2N -PG-OMe (9)

Yellow, sticky liquid; yield: 12.01 g (98%).

IR (cm^{-1}): 2959 (w), 1745 (w), 1665 (s), 1563 (m), 1413 (w), 1370 (w), 1175 (s), 1126 (s), 1027 (w), 983 (w), 832 (m), 798 (m), 720 (s).

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 9.50 (s, 1 H, NH_2^+), 8.99 (t, 3J = 5.8 Hz, 1 H, NH), 8.59 (s, 1 H, NH_2^+), 4.25 (s, 1 H, H-4), 3.96 (m, 2 H, H-6), 3.65 (s, 3 H, H-8), 3.23 (s, 2 H, H-1), 2.33 (m, 1 H, H-2), 1.89 (m, 3 H, H-2 + H-3).

^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 170.2 (C-5), 169.2 (C-7), 59.3 (C-4), 52.4 (C-8), 46.1 (C-1), 41.2 (C-6), 29.9 (C-3), 23.8 (C-2).

MS (ESI, 70 eV): m/z $[\text{M}]^+$ calcd for $[\text{C}_8\text{H}_{15}\text{N}_2\text{O}_3]^+$: 187.1077; found: 187.1083.

Boc-VPG-OMe (10)

White solid; yield: 12.70 g (81%); R_f = 0.3 (DCM-MeOH, 20:1).

IR (cm^{-1}): 3314 (w), 2971 (w), 1751 (w), 1689 (m), 1629 (w), 1509 (w), 1435 (w), 1390 (w), 1365 (w), 1204 (w), 1163 (s), 1090 (w), 1043 (w), 1013 (w), 881 (w).

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.20 (t, 3J = 5.6 Hz, 1 H, NH), 6.73 (d, 3J = 8.4 Hz, 1 H, NH), 4.35 (dd, J = 8.2, 3.7 Hz, 1 H, H_{11}), 3.98 (t, 3J = 8.2 Hz, 1 H, H-4), 3.85 (m, 2 H, H-13), 3.60 (m, 5 H, H-8 + H-15), 2.03 (m, 1 H, H-5), 1.83 (m, 4 H, H-9 + H-10), 0.89 (dd, J = 21.9, 6.6 Hz, 6 H, H-6).

^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 172.6 (C-7), 170.8 (C-12), 170.7 (C-14), 156.0 (C-3), 78.4 (C-2), 59.5 (C-11), 57.7 (C-4), 52.1 (C-15), 47.4 (C-8), 41.0 (C-13), 30.2 (C-5), 29.6 (C-10), 28.6 (C-1), 24.9 (C-9), 19.6 (C-6), 18.8 (C-6).

MS (ESI, 70 eV): m/z $[\text{M} + \text{Na}]^+$ calcd for $[\text{C}_{18}\text{H}_{31}\text{N}_3\text{O}_6\text{Na}]^+$: 408.2096; found: 408.2105.

Boc-VPG-OH (11)

White solid; yield: 11.81 g (97%).

IR (cm^{-1}): 3312 (w), 2972 (w), 1628 (m), 1519 (w), 1443 (w), 1391 (w), 1366 (w), 1242 (w), 1161 (s), 1043 (w), 1015 (w), 878 (w), 602 (w).

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 12.49 (s, 1 H, COOH), 8.08 (t, 3J = 5.6 Hz, 1 H, NH), 6.72 (d, 3J = 8.5 Hz, 1 H, NH), 4.37 (dd, J = 8.2, 3.5 Hz, 1 H, H-11), 3.99 (t, 3J = 8.2 Hz, 1 H, H-4), 3.78 (m, 4 H, H-8 + H-13), 2.03 (m, 1 H, H-5), 1.85 (m, 4 H, H-9 + H-10), 0.89 (dd, J = 22.6, 6.7 Hz, 6 H, H-6).

^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 172.3 (C-7), 171.6 (C-14), 170.8 (C-12), 155.9 (C-3), 78.4 (C-2), 59.5 (C-11), 57.7 (C-4), 47.4 (C-8), 41.0 (C-13), 30.2 (C-5), 29.6 (C-10), 28.6 (C-1), 24.9 (C-9), 19.6 (C-6), 18.8 (C-6).

MS (ESI, 70 eV): m/z $[\text{M} - \text{H}]^-$ calcd for $[\text{C}_{17}\text{H}_{28}\text{N}_3\text{O}_6]^-$: 370.2098; found: 370.1973.

TFA- H_2N -VPG-OMe (12)

Yellow, sticky liquid; yield: 66.5 mg (98%).

^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ = 8.37 (t, 3J = 5.8 Hz, 1 H, NH), 8.06 (s, 3 H, NH_3^+), 4.42 (dd, J = 8.4, 5.1 Hz, 1 H, H-8), 3.97 (m, 1 H, H-3), 3.87 (m, 2 H, H-10), 3.60 (m, 5 H, H-5 + H-12), 2.11 (m, 2 H, H-2 + H-7), 1.81 (m, 3 H, H-6 + H-7), 0.99 (dd, J = 31.8, 6.9 Hz, 6 H, H-1).

^{13}C NMR (100 MHz, $\text{DMSO}-d_6$): δ = 172.0 (C-4), 170.6 (C-9), 167.2 (C-11), 59.8 (C-8), 56.2 (C-3), 52.1 (C-12),

47.8 (C-5), 40.9 (C-10), 27.9 (C-2), 29.7 (C-7), 25.0 (C-6), 18.9 (C-1), 17.5 (C-1).

Boc-VPGVG-OMe (13)

White solid; yield: 12.65 g (73%); R_f = 0.16 (DCM-MeOH, 20:1).

IR (cm^{-1}): 3311 (w), 2966 (w), 1746 (w), 1626 (s), 1522 (m), 1439 (w), 1390 (w), 1366 (w), 1311 (w), 1207 (w), 1162 (s), 1039 (w), 1013 (w), 675 (w), 563 (w).

^1H NMR (400 MHz, DMSO- d_6): δ = 8.38 (t, 3J = 5.8 Hz, 1 H, NH), 8.21 (t, 3J = 5.5 Hz, 1 H, NH), 7.58 (d, 3J = 8.9 Hz, 1 H, NH), 6.72 (d, 3J = 8.3 Hz, 1 H, NH), 4.29 (dd, J = 7.5, 5.0 Hz, 1 H, H-4), 4.15 (dd, J = 8.7, 7.3 Hz, 1 H, H-11), 3.96 (t, 3J = 8.3 Hz, 1 H, H-15), 3.82 (m, 2 H, H-19), 3.71 (m, 3 H, H-8 + H-13), 3.60 (m, 4 H, H-8 + H-21), 1.92 (m, 6 H, H-5 + H-9 + H-10 + H-16), 1.35 (s, 9 H, H-1), 0.86 (m, 12 H, H-6 + H-17).

^{13}C NMR (100 MHz, DMSO- d_6): δ = 172.5 (C-7), 171.8 (C-18), 171.0 (C-12), 170.6 (C-20), 169.1 (C-14), 156.0 (C-3), 78.4 (C-2), 60.1 (C-15), 58.1 (C-11), 57.8 (C-4), 52.1 (C-21), 47.6 (C-8), 42.6 (C-13), 41.0 (C-19), 30.9 (C-16), 30.2 (C-5), 29.6 (C-10), 28.6 (C-1), 25.0 (C-9), 19.5 (C-17), 19.5 (C-6), 18.9 (C-6), 18.6 (C-17).

MS (ESI, 70 eV): m/z $[\text{M} + \text{Na}]^+$ calcd for $[\text{C}_{25}\text{H}_{43}\text{N}_5\text{O}_8\text{Na}]^+$: 564.3014; found: 564.3004.

TFA- H_2N -VPGVG-OMe (14)

Yellow solid; yield: 2.45 g (96%).

IR (cm^{-1}): 3290 (w), 2967 (w), 1748 (w), 1644 (s), 1524 (m), 1454 (w), 1731 (w), 1199 (s), 1176 (s), 1132 (s), 1036 (w), 835 (w), 800 (w), 720 (w), 599 (w).

^1H NMR (400 MHz, DMSO- d_6): δ = 8.42 (t, 3J = 5.9 Hz, 1 H, NH), 8.20 (t, 3J = 5.7 Hz, 1 H, NH), 8.01 (s, 3 H, NH_3^+), 7.67 (dd, 3J = 8.8 Hz, 1 H, NH), 4.42 (dd, J = 8.3, 5.3 Hz, 1 H, H-3), 4.18 (dd, J = 8.8, 6.7 Hz, 1 H, H-8), 3.95 (m, 1 H, H-12), 3.83 (m, 2 H, H-16), 3.70 (m, 3 H, H-5 + H-10), 3.60 (s, 3 H, H-18), 3.50 (m, 1 H, H-5), 2.09–1.82 (m, 6 H, H-2 + H-6 + H-7 + H-13), 0.87 (m, 12 H, H-1 + H-14).

^{13}C NMR (100 MHz, DMSO- d_6): δ = 171.8 (C-4 + C-15), 170.6 (C-9), 169.0 (C-11), 167.3 (C-17), 60.0 (C-12), 57.8 (C-8), 56.2 (C-3), 52.1 (C-18), 47.9 (C-5), 42.4 (C-10), 40.9 (C-16), 31.1 (C-13), 29.7 (C-2 + C-7), 25.0 (C-6), 19.5 (C-14), 18.9 (C-14), 18.4 (C-1), 17.6 (C-1).

MS (ESI, 70 eV): m/z $[\text{M}]^+$ calcd for $[\text{C}_{20}\text{H}_{36}\text{N}_5\text{O}_6]^+$: 442.2660; found: 442.2680.

Boc-VPGVG-OH (15)

White solid; yield: 2.83 g (98%).

IR (cm^{-1}): 3298 (w), 2968 (w), 1627 (s), 1521 (m), 1447 (w), 1391 (w), 1367 (w), 1162 (m), 1015 (w), 878 (w), 677 (w), 620 (w).

^1H NMR (400 MHz, DMSO- d_6): δ = 12.48 (s, 1 H, COOH), 8.27 (t, 3J = 5.9 Hz, 1 H, NH), 8.21 (t, 3J = 5.6 Hz, 1 H, NH), 7.59 (d, 3J = 9.0 Hz, 1 H, NH), 6.71 (d, 3J = 8.4 Hz, 1

H, NH), 4.30 (dd, J = 7.5, 5.3 Hz, 1 H, H-4), 4.16 (dd, J = 8.8, 7.2 Hz, 1 H, H-11), 3.96 (t, 3J = 8.3 Hz, 1 H, H-15), 3.73 (m, 5 H, H-8 + H-13 + H-19), 3.56 (m, 1 H, H-8), 1.94 (m, 6 H, H-5 + H-9 + H-10 + H-16), 1.35 (s, 9 H, H-1), 0.85 (m, 12 H, H-6 + H-17).

^{13}C NMR (100 MHz, DMSO- d_6): δ = 172.4 (C-7), 171.6 (C-18 + C-20), 171.0 (C-12), 169.1 (C-14), 156.0 (C-3), 78.4 (C-2), 60.1 (C-15), 58.1 (C-11), 57.8 (C-4), 47.6 (C-8), 42.6 (C-13), 41.0 (C-19), 31.0 (C-16), 30.2 (C-5), 29.6 (C-10), 28.6 (C-1), 25.0 (C-9), 19.6 (C-17), 19.5 (C-6), 18.9 (C-6), 18.6 (C-17).

MS (ESI, 70 eV): m/z $[\text{M} - \text{H}]^-$ calcd for $[\text{C}_{24}\text{H}_{40}\text{N}_5\text{O}_8]^-$: 526.2871; found: 526.2959.

TFA- H_2N -VPGVG-OH (16)

White solid; yield: 154 mg (98%).

IR (cm^{-1}): 2969 (w), 1642 (s), 1523 (m), 1372 (w), 1179 (s), 1133 (s), 1034 (w), 835 (w), 799 (w), 720 (w), 599 (w).

^1H NMR (400 MHz, DMSO- d_6): δ = 12.43 (s, 1 H, COOH), 8.31 (t, 3J = 6.0 Hz, 1 H, NH), 8.20 (t, 3J = 5.7 Hz, 1 H, NH), 8.03 (s, 3 H, NH_3^+), 7.67 (d, 3J = 8.9 Hz, 1 H, NH), 4.41 (dd, J = 8.2, 5.2 Hz, 1 H, H-3), 4.18 (dd, J = 10.4, 5.0 Hz, 1 H, H-8), 3.95 (m, 1 H, H-12), 3.70 (m, 5 H, H-5 + H-10 + H-16), 3.50 (m, 1 H, H-5), 2.09 (m, 2 H, H-2 + H-13), 1.95 (m, 2 H, H-6 + H-7), 1.82 (m, 2 H, H-6 + H-7), 0.92 (m, 12 H, H-1 + H-14).

^{13}C NMR (100 MHz, DMSO- d_6): δ = 171.8 (C-4), 171.6 (C-17), 171.5 (C-15), 171.0 (C-12), 168.9 (C-11), 167.3 (C-9), 60.0 (C-12), 57.8 (C-8), 56.2 (C-3), 47.8 (C-5), 42.4 (C-10), 41.0 (C-16), 31.1 (C-13), 29.8 (C-7), 29.7 (C-2), 25.0 (C-6), 19.6 (C-14), 18.9 (C-14), 18.4 (C-1), 17.6 (C-1).

MS (ESI, 70 eV): m/z $[\text{M} - \text{H}]^-$ calcd for $[\text{C}_{19}\text{H}_{32}\text{N}_5\text{O}_6]^-$: 426.2347; found: 426.2336.

Boc-(VPGVG) $_2$ -OMe (17)

White solid; yield: 2.67 g (70%); R_f = 0.12 (DCM-MeOH, 10:1).

IR (cm^{-1}): 3300 (w), 2965 (w), 1626 (s), 1518 (m), 1440 (w), 1390 (w), 1367 (w), 1206 (w), 1164 (m), 1012 (w), 879 (w), 665 (w), 614 (w).

^1H NMR (400 MHz, DMSO- d_6): δ = 8.39 (t, 3J = 5.9 Hz, 1 H, NH), 8.26 (t, 3J = 5.8 Hz, 1 H, NH), 8.20 (t, 3J = 5.7 Hz, 1 H, NH), 8.16 (t, 3J = 5.8 Hz, 1 H, NH), 7.90 (d, 3J = 8.5 Hz, 1 H, NH), 7.62 (d, 3J = 8.9 Hz, 2 H, NH), 6.78 (d, 3J = 8.4 Hz, 1 H, NH), 4.27 (m, 3 H, H-4 + H-15), 4.16 (m, 2 H, H-11), 3.97 (t, 3J = 8.4 Hz, 1 H, H-4), 3.73 (m, 10 H, H-8 + H-13 + H-19), 3.60 (m, 5 H, H-8 + H-21), 1.92 (m, 12 H, H-5 + H-9 + H-10 + H-16), 1.35 (s, 9 H, H-1), 0.87 (m, 24 H, H-6 + H-17).

^{13}C NMR (100 MHz, DMSO- d_6): δ = 171.9 (C-7), 171.9 (C-7), 171.3 (C-18), 170.9 (C-18), 170.8 (C-12), 170.1 (C-20), 169.8 (C-12), 168.6 (C-20), 168.6 (C-14), 168.6 (C-14), 155.5 (C-3), 78.0 (C-2), 59.7 (C-15), 59.5 (C-15), 58.3 (C-11), 57.5 (C-11), 57.4 (C-4), 55.6 (C-4), 51.6 (C-21), 47.3

(C-8), 47.2 (C-8), 42.1 (C-13), 42.0 (C-13), 41.6 (C-19), 40.5 (C-19), 30.5 (C-16), 30.4 (C-16), 30.1 (C-5), 29.7 (C-5), 29.2 (C-10), 29.1 (C-10), 28.2 (C-1), 24.6 (C-9), 24.4 (C-9), 19.1 (C-17), 19.0 (C-6 + C-17), 19.0 (C-6), 18.5 (C-17), 18.4 (C-6), 18.3 (C-17), 18.0 (C-6).

MS (ESI, 70 eV): m/z $[M + Na]^+$ calcd for $[C_{44}H_{74}N_{10}O_{13}Na]^+$: 973.5329; found: 973.5324.

TFA·H₂N-(VPGVG)₂-OMe (**18**)

Yellow solid; yield: 860 mg (98%).

IR (cm⁻¹): 3299 (w), 2965 (w), 1749 (w), 1641 (s), 1522 (m), 1448 (w), 1200 (m), 1173 (m), 1034 (w), 835 (w), 719 (w), 701 (w), 602 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 8.42 (t, ³J = 5.9 Hz, 1 H, NH), 8.20 (dd, J = 12.3 Hz, 5.9 Hz, 2 H, NH), 8.16 (t, ³J = 5.8 Hz, 1 H, NH), 8.02 (s, 3 H, NH₃⁺), 7.89 (d, ³J = 8.6 Hz, 1 H, NH), 7.69 (d, ³J = 8.7 Hz, 1 H, NH), 7.62 (d, ³J = 8.9 Hz, 1 H, NH), 4.43 (dd, J = 8.3, 5.3 Hz, 1 H, H-3), 4.32 (m, 2 H, H-8), 4.18 (m, 2 H, H-12), 3.97 (m, 1 H, H-3), 3.73 (m, 10 H, H-5 + H-10 + H-16), 3.62 (s, 3 H, H-18), 3.49 (m, 2 H, H-5), 2.13–1.79 (m, 12 H, H-2 + H-6 + H-7 + H-13), 0.87 (m, 24 H, H-1 + H-14).

¹³C NMR (100 MHz, DMSO-d₆): δ = 172.3 (C-4), 171.8 (C-4 + C-15), 171.5 (C-15), 170.6 (C-9), 170.3 (C-9), 169.1 (C-11), 169.0 (C-11), 168.9 (C-17), 167.3 (C-17), 60.0 (C-12), 59.9 (C-12), 58.1 (C-8), 57.9 (C-8), 56.2 (C-3), 56.1 (C-3), 52.1 (C-18), 47.9 (C-5), 47.6 (C-5), 42.5 (C-10), 42.4 (C-10), 42.0 (C-16), 41.0 (C-16), 31.0 (C-13), 31.0 (C-13), 30.6 (C-2), 29.8 (C-2), 29.7 (C-7), 29.7 (C-7), 25.1 (C-6), 24.9 (C-6), 19.6 (C-14), 19.5 (C-1), 18.9 (C-14), 18.5 (C-1), 18.5 (C-14), 17.6 (C-1).

MS (ESI, 70 eV): m/z $[M]^+$ calcd for $[C_{39}H_{67}N_{10}O_{11}]^+$: 851.4975; found: 851.4985.

Boc-(VPGVG)₂-OH (**19**)

White solid; yield: 849 mg (91%).

IR (cm⁻¹): 3287 (w), 2965 (w), 1622 (s), 1523 (m), 1444 (w), 1390 (w), 1367 (w), 1236 (w), 1165 (m), 1042 (w), 880 (w), 660 (w), 618 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 12.47 (s, 1 H, COOH), 8.27 (dd, J = 11.2, 5.6 Hz, 2 H, NH), 8.20 (t, ³J = 5.7 Hz, 1 H, NH), 8.16 (t, ³J = 5.8 Hz, 1 H, NH), 7.92 (d, ³J = 8.5 Hz, 1 H, NH), 7.61 (t, ³J = 9.4 Hz, 2 H, NH), 6.80 (d, ³J = 8.5 Hz, 1 H, NH), 4.29 (m, 3 H, H-4 + H-11), 4.17 (dd, J = 8.9, 6.9 Hz, 1 H, H-11), 4.10 (dd, J = 8.6, 7.8 Hz, 1 H, H-15), 3.97 (t, ³J = 8.3 Hz, 1 H, H-15), 3.73 (m, 10 H, H-8 + H-13 + H-19), 3.56 (m, 2 H, H-8), 1.94 (m, 12 H, H-5 + H-9 + H-10 + H-16), 1.35 (s, 9 H, H-1), 0.83 (m, 24 H, H-6 + H-17).

¹³C NMR (100 MHz, DMSO-d₆): δ = 172.0 (C-7), 171.9 (C-7), 171.1 (C-18), 171.1 (C-12), 171.0 (C-18), 170.8 (C-12), 169.8 (C-20), 168.6 (C-14), 168.6 (C-20), 155.5 (C-3), 78.0 (C-2), 59.7 (C-15), 59.5 (C-15), 58.3 (C-11), 57.5 (C-11), 57.4 (C-4), 55.6 (C-4), 47.2 (C-8), 47.2 (C-8), 42.1

(C-13), 42.0 (C-13), 41.6 (C-19), 40.6 (C-19), 30.6 (C-16), 30.5 (C-16), 30.1 (C-5), 29.8 (C-5), 29.2 (C-10), 29.1 (C-10), 28.2 (C-1), 24.6 (C-9), 24.4 (C-9), 19.1 (C-17), 19.1 (C-17), 19.0 (C-6), 18.4 (C-17), 18.3 (C-6), 18.0 (C-6).

MS (ESI, 70 eV): m/z $[M - H]^-$ calcd for $[C_{43}H_{71}N_{10}O_{13}]^-$: 935.5197; found: 935.5189.

Boc-(VPGVG)₄-OMe (**20**)

Slightly yellow solid; yield: 704 mg (44%), R_f = 0.29 (DCM-MeOH, 5:1).

IR (cm⁻¹): 3298 (w), 2967 (w), 1627 (s), 1523 (m), 1443 (w), 1391 (w), 1369 (w), 1202 (w), 1172 (m), 1132 (w), 10126(w), 719 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 8.39 (t, ³J = 5.9 Hz, 1 H, NH), 8.20 (m, 7 H, NH), 7.92 (m, 3 H, NH), 7.62 (d, ³J = 8.8 Hz, 4 H, NH), 6.79 (d, ³J = 8.4 Hz, 1 H, NH), 4.28 (m, 7 H, H-4 + H-15), 4.15 (m, 4 H, H-11), 3.97 (t, ³J = 8.4 Hz, 1 H, H-4), 3.72 (m, 20 H, H-8 + H-13 + H-16), 3.60 (m, 7 H, H-8 + H-21), 1.92 (m, 24 H, H-5 + H-9 + H-10 + H-16), 1.35 (s, 9 H, H-1), 0.87 (m, 48 H, H-6 + H-17).

MS (ESI, 70 eV): m/z $[M + Na]^+$ calcd for $[C_{82}H_{136}N_{20}O_{23}Na]^+$: 1791.9979; found: 1791.9966.

TFA·H₂N-(VPGVG)₄-OMe (**21**)

Yellow solid; yield: 702 mg (99%).

IR (cm⁻¹): 3287 (w), 2965 (w), 1627 (s), 1525 (m), 1448 (w), 1200 (w), 1177 (w), 1131 (w), 719 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 8.40 (t, ³J = 5.8 Hz, 1 H, NH), 8.19 (m, 7 H, NH), 8.03 (m, 3 H, NH₃⁺), 7.91 (m, 3 H, NH), 7.61 (d, ³J = 8.8 Hz, 4 H, NH), 4.42 (dd, J = 8.2, 5.3 Hz, 1 H, H-3), 4.31 (m, 6 H, H-3 + H-8), 4.15 (m, 4 H, H-12), 3.96 (m, 1 H, H-3), 3.72 (m, 20 H, H-5 + H-10 + H-16), 3.60 (m, 7 H, H-5 + H-18), 1.94 (m, 24 H, H-2 + H-6 + H-7 + H-13), 0.83 (m, 48 H, H-1 + H-14).

MS (ESI, 70 eV): m/z $[M]^+$ calcd for $[C_{77}H_{129}N_{20}O_{21}]^+$: 1669.9636; found: 1669.9434.

General Procedure for the Peptide Coupling to [Cu(C₁₀COOH-NHC)₂]Br

$[Cu(C_{10}COOH-NHC)_2]Br$ (65 μ mol; 1.0 equiv.) was dissolved in DMF (500 μ L). The mixture was cooled down to 0 °C in an ice bath and a molecular sieve (3 Å) and DCC (0.143 mmol; 2.2 equiv.) were added. The mixture was stirred for 10 min before pentafluorophenol (0.143 mmol; 2.2 equiv.), dissolved in DMF (200 μ L), was added. After stirring for another 15 min, the Boc-protected peptide (0.130 mmol; 2.0 equiv.) was dissolved in DMF (500 μ L) and DIPEA (0.286 mmol; 4.4 equiv.) and added to the reaction mixture. The reaction was further stirred for 42 h. The formed precipitate was removed by filtration and the product was concentrated in vacuum. Purification by column chromatography yielded the pure product.

[Cu(C₁₀COOH-VG-NHC)₂]Br (22a)

White solid; yield: 26.2 mg (42%); *R_f* = 0.18 (CHCl₃-MeOH, 20:1).

IR (cm⁻¹): 3284 (s), 2923 (s), 2852 (m), 1735 (m), 1668 (s), 1631 (s), 1631 (s), 1544 (m), 1469 (w), 1409 (w), 1387 (w), 1341 (w), 1296 (w), 1240 (m), 1152 (w), 1112 (w), 1041 (w), 1013 (w), 846 (w), 674 (m).

¹H NMR (400 MHz, CDCl₃): δ = 6.97 (t, ³*J* = 5.3 Hz, 1 H, NH), 6.27 (d, ³*J* = 8.7 Hz, 1 H, NH), 6.14 (dd, 2 H, H-3 + H-4), 4.35 (dd, ³*J* = 7.0 Hz, 1 H, H-11), 4.07 + 3.95 (dd, 1 H, H-15), 3.72 (s, 3 H, H-17), 3.56 (m, 2 H, H-5), 3.22 (s, 3 H, H-1), 2.20 (t, ³*J* = 7.6 Hz, 2 H, H-9), 2.09 (m, 1 H, H-12), 1.59 (m, 4 H, H-6 + H-8), 1.24 (m, 12 H, H-7), 0.94 (dd, *J* = 8.8, 6.8 Hz, 6 H, H-13).

¹³C NMR (100 MHz, CDCl₃): δ = 173.3 (C-10), 171.8 (C-14), 169.9 (C-16), 153.2 (C-2), 111.1 (C-4), 109.9 (C-3), 58.1 (C-11), 52.2 (C-17), 43.6 (C-5), 41.1 (C-15), 36.6 (C-1), 31.0 (C-12), 30.3 (C-9), 29.5 (C-6), 29.3 (C-7), 29.2 (C-7), 29.2 (C-7), 29.1 (C-7), 29.1 (C-7), 26.5 (C-7), 25.6 (C-8), 19.1 (C-13), 18.2 (C-13).

[Cu(C₁₀COOH-VPG-NHC)₂]Br (22b)

Colorless, sticky liquid; yield: 31.7 mg (31%); *R_f* = 0.11 (CHCl₃-MeOH, 40:1).

IR (cm⁻¹): 3289 (m), 1926 (s), 2854 (m), 1753 (m), 1629 (s), 1531 (m), 1436 (s), 1369 (m), 1237 (m), 1201 (s), 1108 (w), 1013 (w), 662 (m).

¹H NMR (400 MHz, CDCl₃): δ = 7.30 (t, ³*J* = 4.9 Hz, 1 H, NH), 6.16 (d, ³*J* = 9.0 Hz, 1 H, NH), 6.14 (dd, 2 H, H-3 + H-4), 4.60 (m, 2 H, H-11 + H-18), 3.99 (m, 2 H, H-20), 3.71 (m, 5 H, H-15 + H-22), 3.55 (t, ³*J* = 7.3 Hz, 2 H, H-5), 3.22 (s, 3 H, H-1), 2.33 (m, 1 H, H-12), 2.18 (t, ³*J* = 7.6 Hz, 2 H, H-9), 2.00 (m, 4 H, H-16 + H-17), 1.61 (m, 4 H, H-6 + H-8), 1.25 (m, 12 H, H-7), 0.92 (dd, *J* = 23.9, 6.7 Hz, 6 H, H-13).

¹³C-NMR (100 MHz, CDCl₃): δ = 173.1 (C-10), 172.3 (C-14), 171.2 (C-19), 170.0 (C-21), 153.2 (C-2), 111.0 (C-4), 109.9 (C-3), 59.7 (C-18), 55.3 (C-11), 52.2 (C-22), 47.7 (C-15), 43.6 (C-5), 41.2 (C-20), 36.6 (C-1), 31.4 (C-12), 30.3 (C-9), 29.5 (C-6), 29.3 (C-7), 29.3 (C-7), 29.2 (C-7), 29.1 (C-7), 27.2 (C-17), 26.5 (C-7), 25.6 (C-8), 25.0 (C-16), 19.4 (C-13), 17.7 (C-13).

[Cu(C₁₀COOH-VPGVG-NHC)₂]Br (22c)

White solid; yield: 37.4 mg (38%); *R_f* = 0.08 (CHCl₃-MeOH, 20:1).

IR (cm⁻¹): 3305 (w), 2929 (w), 2855 (w), 1754 (w), 1652 (s), 1544 (w), 1412 (m), 1387 (m), 1312 (s), 1206 (w), 1104 (w), 1037 (w), 824 (w), 672 (m).

¹H NMR (400 MHz, DMSO-d₆): δ = 8.41 (t, ³*J* = 5.9 Hz, 1 H, NH), 8.18 (t, ³*J* = 5.8 Hz, 1 H, NH), 7.93 (d, ³*J* = 8.4 Hz, 1 H, NH), 7.63 (d, ³*J* = 8.9 Hz, 1 H, NH), 6.46 (dd, 2 H, H-3 + H-4), 4.30 (m, 2 H, H-11 + H-22), 4.18 (dd, *J* = 8.8,

7.0 Hz, 1 H, H-18), 3.81 (m, 4 H, H-20 + H-26), 3.62 (m, 5 H, H-15 + H-28), 3.45 (t, ³*J* = 7.1 Hz, 2 H, H-5), 3.09 (s, 3 H, H-1), 2.17–1.78 (m, 8 H, H-9 + H-12 + H-16 + H-17 + H-23), 1.53 (m, 2 H, H-6), 1.46 (m, 2 H, H-8), 1.22 (s, 12 H, H-7), 0.82 (m, 12 H, H-13 + H-24).

¹³C NMR (100 MHz, DMSO-d₆): δ = 172.5 (C-14), 172.4 (C-10), 171.8 (C-25), 170.7 (C-21), 170.6 (C-27), 169.1 (C-19), 153.0 (C-2), 111.7 (C-4), 110.6 (C-3), 59.9 (C-22), 58.0 (C-18), 56.2 (C-11), 52.1 (C-28), 47.6 (C-15), 43.0 (C-5 + C-20), 41.0 (C-26), 35.3 (C-1), 31.0 (C-23), 30.3 (C-12), 30.2 (C-9), 29.7 (C-17), 29.4 (C-6), 29.3 (C-7), 29.1 (C-7), 29.0 (C-7), 29.0 (C-7), 26.4 (C-7), 25.7 (C-8), 24.9 (C-16), 19.6 (C-24), 19.5 (C-13), 19.0 (C-24), 18.5 (C-13).

[Cu(C₁₀COOH-(VPGVG)₂-NHC)₂]Br (22d)

White solid; yield: 32.7 mg (11%); *R_f* = 0.26 (DCM-MeOH, 10:1).

IR (cm⁻¹): 3288 (w), 2931 (w), 1648 (s), 1526 (m), 1445 (w), 1202 (w), 1130 (w), 836 (w), 800 (w), 720 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 8.41 (t, ³*J* = 5.9 Hz, 1 H, NH), 8.21 (m, 3 H, NH), 7.95 (t, ³*J* = 8.1 Hz, 2 H, NH), 7.64 (d, ³*J* = 8.9 Hz, 1 H, NH), 6.45 (dd, 2 H, H-3 + H-4), 4.30 (m, 4 H, H-11 + H-22), 4.15 (m, 2 H, H-18), 3.73 (m, 10 H, H-15 + H-20 + H-26), 3.62 (m, 5 H, H-15 + H-28), 3.45 (t, ³*J* = 7.1 Hz, 2 H, H-5), 3.09 (s, 3 H, H-1), 2.18–1.79 (m, 14 H, H-9 + H-12 + H-16 + H-17 + H-23), 1.53 (m, 2 H, H-6), 1.46 (m, 2 H, H-8), 1.21 (s, 12 H, H-7), 0.84 (m, 24 H, H-13 + H-24).

¹³C NMR (100 MHz, DMSO-d₆): δ = 172.1 (C-14), 171.9 (C-14), 171.9 (C-10), 171.3 (C-25), 171.0 (C-25), 170.5 (C-19), 170.1 (C-19), 169.8 (C-27), 168.6 (C-27), 168.6 (C-21), 168.6 (C-21), 152.5 (C-2), 111.3 (C-4), 110.1 (C-3), 59.6 (C-22), 59.5 (C-22), 58.1 (C-18), 57.5 (C-18), 55.8 (C-11), 55.7 (C-11), 51.6 (C-28), 47.3 (C-15), 47.2 (C-15), 42.5 (C-5 + C-20), 40.5 (C-26), 40.2 (C-26), 34.9 (C-1), 30.5 (C-23), 30.1 (C-12), 29.9 (C-12), 29.8 (C-9), 29.2 (C-17), 29.2 (C-17), 28.9 (C-6), 28.8 (C-7), 28.7 (C-7), 28.6 (C-7), 28.5 (C-7), 25.9 (C-7), 25.3 (C-8), 24.4 (C-16), 24.4 (C-16), 19.1 (C-24), 19.0 (C-13), 18.6 (C-24), 18.4 (C-13), 18.3 (C-24), 18.0 (C-13).

[Cu(C₁₀COOH-(VPGVG)₄-NHC)₂]Br (22e)

Yellow solid; yield: 107 mg (14%); *R_f* = 0.18 (DCM-MeOH, 5:1).

IR (cm⁻¹): 3285 (w), 2964 (w), 1752 (w), 1620 (s), 1523 (m), 1443 (w), 1202 (w), 1131 (w), 1034 (w), 660 (w).

¹H NMR (400 MHz, DMSO-d₆): δ = 8.40 (t, ³*J* = 5.9 Hz, 2 H, NH), 8.18 (m, 6 H, NH), 7.92 (m, 4 H, NH), 7.62 (d, ³*J* = 8.8 Hz, 4 H, NH), 6.44 (dd, 2 H, H-3 + H-4), 4.30 (m, 8 H, H-11 + H-22), 4.12 (m, 4 H, H-18), 3.72 (m, 20 H, H-15 + H-20 + H-26), 3.60 (m, 7 H, H-15 + H-28), 3.43 (m, 2 H, H-5), 3.07 (s, 3 H, H-1), 2.18–1.72 (m, 26 H, H-

9 + H-12 + H-16 + H-17 + H-23), 1.49 (m, 2 H, H-6), 1.43 (m, 2 H, H-8), 1.20 (s, 12 H, H-7), 0.82 (m, 48 H, H-13 + H-24).

Synthesis of Benzyl Azide (23)

Sodium azide (5.5 g, 84.7 mmol) and benzyl bromide (13.2 g, 9.17 mL, 77.0 mmol) were dissolved in DMSO (170.0 mL). The reaction mixture was stirred at 40 °C for 90 h. Afterwards water (50.0 mL) was added and the reaction was further stirred, until it cooled down to room temperature. The mixture was extracted with Et₂O (3 × 30.0 mL) and the combined organic phases were washed with water (2 × 50.0 mL) and brine (50.0 mL). Subsequently the organic phase was dried over Na₂SO₄, filtered, and the solvent was removed under reduced pressure.

Yellow solution; yield: 9.45 g (92%).

IR: ν_{max} (cm⁻¹): 3032 (w), 2090 (s), 1496 (w), 1454 (w), 1349 (w), 1253 (m), 1201 (w), 1077 (w), 1028 (w), 875 (w), 736 (m), 697 (s), 651 (w), 566 (w).

¹H NMR (400 MHz, CDCl₃): δ = 7.38 (m, 5 H, H-3 + H-4 + H-5), 4.35 (s, 2 H, H-1).

¹³C NMR (100 MHz, CDCl₃): δ = 135.4 (C-2), 129.0 (C-4), 128.3 (C-5), 128.2 (C-3), 54.8 (C-1).

Funding Information

The authors are thankful for grants from the Sonderforschungsbereich/Transregio (SFB/TRR) 102 (TP A03 and A12) and the DFG (grant within the SPP 1568). The authors also thank the Leistungszentrum "System- und Biotechnologie" (Uni-CBS1) for financial support for the project "Biologisch abbaubare Partikel über Enkapsulierungsmethoden: Emulsions-/Evaporationsverfahren und 3D-Printing".

Acknowledgments

The authors thank MSc Jan Freudenberg for assistance during the CD and IR measurements in solution and Dr. Philipp Michael for helpful discussions and critical remarks while preparing the manuscript.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0040-1702149>.

References

- (1) Anwar, R. A. *Biochem. Educ.* **1990**, 18, 162.
- (2) Li, B.; Daggett, V. J. *Muscle. Res. Cell Motil.* **2002**, 23, 561.
- (3) Keeley, F. W.; Bellingham, C. M.; Woodhouse, K. A. *Philos. Trans. R. Soc. London, Ser. B* **2002**, 357, 185.
- (4) Daamen, W. F.; Veerkamp, J. H.; van Hest, J. C. M.; van Kuppevelt, T. H. *Biomaterials* **2007**, 28, 4378.
- (5) Perticaroli, S.; Ehlers, G.; Jalarvo, N.; Katsaras, J.; Nickels, J. D. *J. Phys. Chem. Lett.* **2015**, 6, 4018.
- (6) Foster, J. A.; Bruenger, E.; Gray, W. R.; Sandberg, L. B. *J. Biol. Chem.* **1973**, 248, 2876.
- (7) Urry, D. W.; Cunningham, W. D.; Ohnishi, T. *Biochemistry* **1974**, 13, 609.
- (8) Sandberg, L. B.; Leslie, J. G.; Leach, C. T.; Alvarez, V. L.; Torres, A. R.; Smith, D. W. *Pathol. Biol.* **1985**, 33, 266.
- (9) Yeh, H.; Ornstein-Goldstein, N.; Indik, Z., et al. *Coll. Relat. Res.* **1987**, 7, 235.
- (10) Urry, D. W.; Long, M. M. *CRC Crit. Rev. Biochem.* **1976**, 4, 1.
- (11) Venkatachalam, C. M.; Urry, D. W. *Macromolecules* **1981**, 14, 1225.
- (12) Urry, D. W.; Trapane, T. L.; Long, M. M.; Prasad, K. U. *J. Chem. Soc., Faraday Trans.* **1983**, 79, 853.
- (13) Urry, D. W.; Venkatachalam, C. M. *Int. J. Quantum Chem.* **1983**, 24, 81.
- (14) Urry, D. W. *J. Protein Chem.* **1988**, 7, 1.
- (15) Urry, D. W. *J. Protein Chem.* **1988**, 7, 81.
- (16) Urry, D. W.; Long, M. M.; Ohnishi, T.; Jacobs, M. *Biochem. Biophys. Res. Commun.* **1974**, 61, 1427.
- (17) Khaled, M. A.; Venkatachalam, C. M.; Sugano, H.; Urry, D. W. *Int. J. Pept. Protein Res.* **1981**, 17, 23.
- (18) Urry, D. W.; Trapane, T. L.; Sugano, H.; Prasad, K. U. *J. Am. Chem. Soc.* **1981**, 103, 2080.
- (19) Tunn, I.; de Léon, A. S.; Blank, K. G.; Harrington, M. J. *Nanoscale* **2018**, 10, 22725.
- (20) López-García, P.; Goktas, M.; Bergues-Pupo, A. E.; Koksche, B.; Varón Silva, D.; Blank, K. G. *Phys. Chem. Chem. Phys.* **2019**, 21, 9145.
- (21) Davis, D. A.; Hamilton, A.; Yang, J.; Cremer, L. D.; Van Gough, D.; Potisek, S. L.; Ong, M. T.; Braun, P. V.; Martínez, T. J.; White, S. R.; Moore, J. S.; Sottos, N. R. *Nature* **2009**, 459, 68.
- (22) Beiermann, B. A.; Davis, D. A.; Kramer, S. L. B.; Moore, J. S.; Sottos, N. R.; White, S. R. *J. Mater. Chem.* **2011**, 21, 8443.
- (23) Zhang, H.; Chen, Y.; Lin, Y.; Fang, X.; Xu, Y.; Ruan, Y.; Weng, W. *Macromolecules* **2014**, 47, 6783.
- (24) Chen, Y.; Sijbesma, R. P. *Macromolecules* **2014**, 47, 3797.
- (25) Clough, J. M.; Balan, A.; van Daal, T. L. J.; Sijbesma, R. P. *Angew. Chem. Int. Ed.* **2016**, 55, 1445.
- (26) Piermattei, A.; Karthikeyan, S.; Sijbesma, R. P. *Nat. Chem.* **2009**, 1, 133.
- (27) Jakobs, R. T. M.; Sijbesma, R. P. *Organometallics* **2012**, 31, 2476.
- (28) Michael, P.; Binder, W. H. *Angew. Chem. Int. Ed.* **2015**, 54, 13918.
- (29) Michael, P.; Sheidaee Mehr, S. K.; Binder, W. H. *J. Polym. Sci., Part A: Polym. Chem.* **2017**, 55, 3893.
- (30) Di Giannantonio, M.; Ayer, M. A.; Verde-Sesto, E.; Lattuada, M.; Weder, C.; Fromm, K. M. *Angew. Chem. Int. Ed.* **2018**, 57, 11445.
- (31) Michael, P.; Biewend, M.; Binder, W. H. *Macromol. Rapid Commun.* **2018**, 39, e1800376.
- (32) Sha, Y.; Zhang, Y.; Xu, E.; Wang, Z.; Zhu, T.; Craig, S. L.; Tang, C. *ACS Macro Lett.* **2018**, 7, 1174.
- (33) Biewend, M.; Neumann, S.; Michael, P.; Binder, W. H. *Polym. Chem.* **2019**, 10, 1078.
- (34) Sha, Y.; Zhang, Y.; Xu, E.; McAlister, C. W.; Zhu, T.; Craig, S. L.; Tang, C. *Chem. Sci.* **2019**, 10, 4959.
- (35) Hickenboth, C. R.; Moore, J. S.; White, S. R.; Sottos, N. R.; Baudry, J.; Wilson, S. R. *Nature* **2007**, 446, 423.
- (36) Larsen, M. B.; Boydston, A. J. *J. Am. Chem. Soc.* **2013**, 135, 8189.
- (37) Larsen, M. B.; Boydston, A. J. *J. Am. Chem. Soc.* **2014**, 136, 1276.

- (38) Diesendruck, C. E.; Steinberg, B. D.; Sugai, N.; Silberstein, M. N.; Sottos, N. R.; White, S. R.; Braun, P. V.; Moore, J. S. *J. Am. Chem. Soc.* **2012**, *134*, 12446.
- (39) Kean, Z. S.; Craig, S. L. *Polymer* **2012**, *53*, 1035.
- (40) Van Der Hoff, B. M. E.; Glynn, P. A. R. *J. Macromol. Sci. Part A Pure Appl. Chem.* **1974**, *8*, 429.
- (41) Van der Hoff, B. M. E.; Gall, C. E. *J. Macromol. Sci. Part A Pure Appl. Chem.* **1977**, *11*, 1739.
- (42) Funtan, S.; Michael, P.; Binder, W. H. *Biomimetics* **2019**, *4*, 24.
- (43) Chen, Y.; Guan, Z. *J. Am. Chem. Soc.* **2010**, *132*, 4577.
- (44) Kong, J.; Yu, S. *Acta Biochim. Biophys. Sin.* **2007**, *39*, 549.
- (45) Serrano, V.; Liu, W.; Franzen, S. *Biophys. J.* **2007**, *93*, 2429.
- (46) Greenfield, N. J. *Nat. Protoc.* **2006**, *1*, 2876.
- (47) Binder, W. H.; Sachsenhofer, R. *Macromol. Rapid Commun.* **2008**, *29*, 952.
- (48) Tisato, F.; Marzano, C.; Porchia, M.; Pellei, M.; Santini, C. *Med. Res. Rev.* **2010**, *30*, 708.
- (49) Gandin, V.; Porchia, M.; Tisato, F.; Zanella, A.; Severin, E.; Dolmella, A.; Marzano, C. *J. Med. Chem.* **2013**, *56*, 7416.
- (50) Li, F.; Bravo-Rodriguez, K.; Phillips, C.; Seidel, R. W.; Wieberneit, F.; Stoll, R.; Doltsinis, N. L.; Sanchez-Garcia, E.; Sander, W. *J. Phys. Chem. B* **2013**, *117*, 3560.
- (51) Maity, S.; Kumar, P.; Haldar, D. *Soft Matter*. **2011**, *7*, 5239.